rezatapopt
rezatapopt: developed by 1 company · 3 clinical trials tracked.
rezatapopt evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could rezatapopt → PMVP affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) TP53 Y220C Mutation; Advanced Solid Tumor | Phase 1 |
Clinical Trials (3)
A Phase 1, Open-label, 2-part, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.
Primary endpoint: Metformin Cmax geometric mean ratio
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Primary endpoint: Safety and adverse events (AEs)
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Primary endpoint: Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt
Frequently asked questions
Who is developing rezatapopt?
rezatapopt is being developed by PMV Pharmaceuticals, Inc..
How many clinical trials involve rezatapopt?
BioSniper tracks 3 clinical trials involving rezatapopt.